Five-Year Hand-Eczema Outcomes in 2,270 Danish Adults
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured image is an AI-created illustration of a fictional work or daily-life scene. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
Reader question: What can this study tell a worker or family—and what would be an overclaim? This review keeps the population, denominator, comparator, timepoint and limitations attached to every number.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 2,270 Danish adults aged 18-72 who participated in a five-year population follow-up; follow-up participation was 66.5% and 29.7% of those originally invited at baseline. |
| Design | Population-based cohort with questionnaire-defined never, incident, nonpersistent and persistent hand-eczema groups. |
| Comparator | Baseline atopic dermatitis, filaggrin null mutations and contact sensitization across incident and persistent outcomes. |
| Timepoint | Five years between baseline and follow-up. |
| Key result | Atopic-dermatitis history predicted persistent (OR 9.0, 95% CI 5.6-14.4) and incident hand eczema (OR 3.0, 1.7-5.2); filaggrin null mutations were associated with persistence, not incidence. |
| Funding/conflict context | The PubMed record lists no grant support for this article. |
What does the result mean?
Atopic-dermatitis history predicted persistent (OR 9.0, 95% CI 5.6-14.4) and incident hand eczema (OR 3.0, 1.7-5.2); filaggrin null mutations were associated with persistence, not incidence.
Incidence and persistence are different questions. The results suggest atopic history matters for both, while the filaggrin signal was concentrated in persistence—an important nuance that a single 'risk factor' label would erase.
The denominator is part of the finding. A clinic sample, compensation registry, online panel or selected occupational group answers a different question from a random general-population cohort. Percentages should remain attached to the people actually studied.
What the study cannot establish
Participation and attrition may bias estimates; outcomes included self-report, and genetic or sensitization associations do not determine an individual's future.
Observational association is not the same as causation. Even when an odds ratio or confidence interval is reported, unmeasured exposure, access to care, reporting practices and selection can influence the estimate. A PubMed record is a bibliographic source; PubMed indexing is not NIH endorsement of the study, this interpretation or any product.
Why job title is not enough
Two people with the same occupation may have different contact with water, cleansers, gloves, resins, metals, food proteins, dust, friction or heat. Conversely, the same exposure can appear at work, during caregiving, hobbies or household tasks. A useful history records the task, material, route, duration and timing—not only the job name.
Symptoms, clinical examination and patch testing answer different questions. A symptom survey may detect a pattern. An examination can refine the differential diagnosis. Patch testing looks for delayed contact sensitization, while immediate reactions may need different evaluation. Occupational relevance still depends on real exposure and timing.
Practical questions to document
- Which exact task, product, glove, metal, resin, cleanser, food, plant, dust or surface preceded the change?
- Where did symptoms appear and how did they change on days away, after process changes or after different protective equipment?
- How often were hands washed, occluded, rubbed, heated, cooled or kept wet?
- Did symptoms affect sleep, dexterity, attendance, pace, safety or the ability to complete a specific task?
- Can labels and safety-data sheets be brought to occupational health without deliberately placing workplace material on skin?
Prevention comes before cosmetic care
Substitution, engineering controls, exposure reduction, training and correctly selected protective equipment are core workplace measures. Gloves are not automatically protective: material, fit, breakthrough time, sweating and glove allergens matter. A moisturizer cannot neutralize an allergen, replace ventilation or make an unsafe process safe.
Seek professional evaluation for persistent, recurrent or spreading symptoms, drainage, fever, breathing symptoms, severe pain, rapidly worsening redness or major loss of function. Individual diagnosis and workplace accommodation require a clinician and, when relevant, occupational health.
Primary research and authoritative guidance
- Primary research record: PubMed PMID 26872425
- NIOSH: occupational skin exposure
- NIAMS: atopic dermatitis overview
- American Academy of Dermatology: eczema skin care
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003. Its findings do not show that #003 treats, cures or prevents eczema, relieves pain or itch, is appropriate for every person, or provides pediatric or 24-hour efficacy.
Continue the evidence series
- Occupational Contact-Dermatitis Exposure Scores Across 230 Hospital Employees
- Skin-Protection Courses for 791 Healthcare, Cleaning and Kitchen Workers
- Job-Exposure Matrix Findings Across 56,978 Dutch Adults
- Smoking, Stress and Obesity Across 57,046 Dutch Adults
Evidence note: This educational article separates reported findings from interpretation and does not provide diagnosis, treatment or a workplace-safety determination.
DR. ARSY SKINCARE
Shop Moisturizer #003
Choose your preferred place to shop.